Alcohol on a GLP-1: what the labels say (almost nothing), what the trials found, and how to drink if you do

Search any GLP-1 forum for "alcohol" and you will find two camps: people who say one drink now floors them, and people who say they have lost interest in drinking altogether. The labels have nothing to say to either camp. This guide sets out what the prescribing information does and does not contain, what is actually known from trials, and how to think about drinking while on semaglutide or tirzepatide.

What the labels say

The drug interaction sections (section 7) of the Zepbound, Mounjaro, Wegovy and Ozempic labels do not mention alcohol. The patient medication guides do not mention it. The clinical pharmacology sections contain no alcohol study. On the narrow question "does the label warn against alcohol", the answer for all four products is no.

That silence is not a clearance. Three warnings elsewhere in the labels intersect with drinking.

Hypoglycaemia. All four labels warn that the risk of hypoglycaemia rises when the drug is used with insulin or an insulin secretagogue such as a sulfonylurea, and that reducing the dose of those drugs may be necessary. Alcohol independently lowers blood glucose by suppressing the liver's glucose output, and the ADA Standards of Care advise people who use insulin or secretagogues to be educated about delayed hypoglycaemia after drinking and to eat when they drink. A GLP-1 alone rarely causes hypoglycaemia in someone without diabetes; a GLP-1 plus a sulfonylurea plus an evening of drinking on a small dinner is a different situation.

Pancreatitis. All four labels carry an acute pancreatitis warning and instruct that the drug be discontinued if pancreatitis is suspected. Heavy alcohol use is one of the two commonest causes of acute pancreatitis in adults. The labels do not quantify any interaction, and the trial rates were low (the Wegovy label reports adjudicated acute pancreatitis in 4 treated patients, 0.2 cases per 100 patient-years, versus 1 on placebo). But two independent risks for the same organ is a reason for caution, and a history of pancreatitis is something every prescriber will ask about.

Gastrointestinal effects and volume depletion. The labels describe nausea, vomiting and diarrhoea as the commonest adverse reactions and warn that they can lead to dehydration and acute kidney injury. Alcohol is a diuretic and a gastric irritant. Drinking during the weeks after a dose escalation, when the label says GI effects are most frequent, stacks one cause of nausea and fluid loss on another.

What the trials found

The large weight-management trials did not restrict alcohol and did not report drinking as an outcome. STEP 1 (Wilding 2021, PubMed 33567185) and SURMOUNT-1 (Jastreboff 2022, PubMed 35658024) tell you nothing about it either way.

One randomised trial has looked directly. Hendershot and colleagues (JAMA Psychiatry 2025, PubMed 39937469) randomised 48 adults with alcohol use disorder who were not seeking treatment to low-dose semaglutide (titrated to 1.0 mg) or placebo for nine weeks. Semaglutide reduced the amount consumed in a laboratory drinking session, reduced drinks per drinking day, and reduced weekly craving compared with placebo; it did not significantly change the number of drinking days. The authors describe it as a phase 2 signal that needs larger trials. Neither semaglutide nor tirzepatide is approved for alcohol use disorder, and nothing in this guide should be read as a suggestion to use one for that purpose.

That trial is consistent with what many people report anecdotally, which is a loss of interest in alcohol rather than a bad reaction to it. Both are real experiences; only one of them has been measured.

Why alcohol might feel different

There is no controlled measurement of blood alcohol on a GLP-1. There are plausible mechanisms, and it is worth being honest that they are mechanisms rather than data.

Both drugs slow gastric emptying, which the labels state. Alcohol is absorbed mainly from the small intestine, so slower emptying would be expected, if anything, to delay the peak rather than raise it. Against that, people on these drugs eat less, and a drink taken on an emptier stomach is absorbed faster and peaks higher. People also lose weight, and the same drink produces a higher blood alcohol concentration in a lighter body. Add nausea, which alcohol worsens, and reflux, which the labels list as an adverse reaction and alcohol aggravates, and the reports of "one glass and I felt terrible" are unsurprising without any pharmacological interaction at all.

Calories, which the label does not count

Alcohol is 7 kcal per gram. A 175 mL glass of wine is roughly 150 kcal; a pint of 5 percent beer roughly 240; a 45 mL measure of spirits roughly 100 before the mixer. The GLP-1 trials that produced the label weight-loss figures all paired the drug with a reduced-calorie diet, and the labels say the drug is indicated as an adjunct to one. Several drinks a week is the kind of intake that people on a suppressed appetite stop noticing, because the drug does not reduce the calories in a glass; it only reduces how much else you want.

If you drink

These are general principles drawn from the label warnings above and the ADA's advice on alcohol; they are not label instructions, and your prescriber's advice overrides them.

Eat something first. This matters most for anyone on insulin or a sulfonylurea, where the ADA specifically advises eating when drinking to reduce hypoglycaemia risk. It also blunts the fast absorption of a drink on an empty stomach.

Start with less than you used to. A lighter body and a slower stomach change the dose-response, and you do not know yours yet.

Avoid the week after a dose increase. The labels say GI adverse reactions cluster during escalation. The dose escalation guide explains what that week looks like and why it is not the time to add a second cause of nausea.

Drink water alongside. Volume depletion from GI effects is a label warning, and the hydration guide explains the acute kidney injury cases behind it.

Know the pancreatitis symptoms: severe persistent abdominal pain, sometimes radiating to the back, with or without vomiting. The labels say to stop the drug and seek medical care if pancreatitis is suspected. Alcohol-related abdominal pain that does not settle is a reason to be seen, not to sleep it off.

Tell your prescriber how much you drink, honestly. Heavy or increasing use changes the risk calculation on pancreatitis, on liver disease, and on whether the drug should be continued.

When alcohol is a reason to talk before starting

A history of pancreatitis, alcohol-related or not. Known gallbladder disease (the labels warn of acute gallbladder disease; the Wegovy label reports cholelithiasis in 1.6 percent of treated adults versus 0.7 percent on placebo). Liver disease. Insulin or sulfonylurea use. Any pattern of drinking you would rather not describe to a doctor, which is itself the reason to describe it.

Compounded products

Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with the brand products whose labels this guide quotes. There is no separate evidence on alcohol with compounded versions; the same active ingredients carry the same mechanisms and the same warnings. FormBlends' semaglutide and tirzepatide pages describe what its pharmacies dispense.